Teva Pharmaceuticals announced on October 9, 2026 that the U.S. Food and Drug Administration has approved Weltruza—olanzapine extended-release injectable suspension—as the first and only once-monthly subcutaneous injectable formulation of olanzapine for adults with schizophrenia. The approval addresses one of the most persistent clinical challenges in psychiatry: keeping patients on their medication long enough to prevent relapse.
The Adherence Problem in Schizophrenia
Schizophrenia affects an estimated 2.1 million people in the United States and roughly 24 million globally. It is a chronic, severe psychiatric disorder characterized by hallucinations, delusions, disorganized thinking, and significant functional impairment. Antipsychotic medications can effectively control symptoms for most patients, but they must be taken consistently—and that is where treatment frequently breaks down.
Daily oral antipsychotics require patients to remember a pill every single day, often for life. Non-adherence rates in schizophrenia are among the highest of any chronic condition: studies consistently show that 40 to 60 percent of patients discontinue or miss doses within the first year. Each relapse carries consequences—psychiatric hospitalization, functional deterioration, increased risk of self-harm, and progressive treatment resistance. Reducing the dosing burden from daily to once monthly is not a convenience play; it is a strategy with direct clinical stakes.
Long-acting injectables, known as LAIs, have existed for antipsychotics since the 1960s, but their uptake has been limited by practical barriers. Previous olanzapine LAIs required post-injection monitoring periods of at least three hours due to the rare but serious risk of post-injection delirium/sedation syndrome associated with intramuscular administration. Weltruza’s subcutaneous formulation is designed to eliminate that requirement entirely.
How Weltruza Works
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors, the two primary molecular targets implicated in psychosis and mood symptoms. While its pharmacology is identical to the oral formulation, the delivery mechanism is entirely new. Weltruza uses Medincell’s proprietary SteadyTeq copolymer technology, which creates a subcutaneous depot that releases olanzapine gradually over 30 days. This controlled-release architecture maintains steady plasma concentrations without the peaks and troughs associated with daily dosing—a smoother pharmacokinetic profile that may also reduce side effects tied to peak concentrations.
Critically, Weltruza requires no loading dose and no oral supplementation to achieve therapeutic levels. Patients begin their once-monthly injection without a transitional period, simplifying the initiation process considerably. Available doses are 318 mg, 425 mg, and 531 mg per month, corresponding to oral equivalents of 10 mg, 15 mg, and 20 mg daily, respectively.
The SOLARIS Trial
FDA approval was supported by data from the SOLARIS trial (NCT05693935), a Phase 3, multinational, randomized, double-blind, placebo-controlled study conducted in adults aged 18 to 64 experiencing an acute schizophrenia exacerbation. In the first eight weeks, 675 patients were randomized 1:1:1:1 to one of three active dose groups—318 mg, 425 mg, or 531 mg—or placebo. This was followed by a 48-week open-label extension.
The primary efficacy measure was change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at week eight. All three doses significantly outperformed placebo: The 318 mg dose produced a PANSS reduction of 9.75 points more than placebo (95% CI: -13.60 to -5.89). The 425 mg dose showed the largest effect at 11.27 points (95% CI: -15.01 to -7.53). The 531 mg dose produced a 9.76-point advantage (95% CI: -13.50 to -6.02). All three doses also demonstrated statistically significant superiority over placebo on the Clinical Global Impression-Severity scale and the Personal and Social Performance scale.
Safety and Tolerability
The most commonly reported adverse events were weight gain, somnolence, headache, constipation, and injection site reactions—a profile consistent with oral olanzapine. Discontinuation rates due to adverse events were low: approximately 5 percent in the active treatment arms versus 4 percent in the placebo arm. Weltruza carries a boxed warning, as do all antipsychotics, for increased mortality risk in elderly patients with dementia-related psychosis.
No post-injection monitoring is required for Weltruza, removing a major logistical barrier that has discouraged use of the existing intramuscular olanzapine LAI (Zyprexa Relprevv) in clinical practice. No suspected or confirmed cases of post-injection delirium/sedation syndrome were identified across approximately 3,487 active injections in the SOLARIS program.
A Meaningful Advancement in Psychiatric Care
For psychiatrists and mental health prescribers, Weltruza fills a specific and practical gap. Olanzapine is one of the most widely prescribed antipsychotics—valued for its robust efficacy across positive, negative, and mood symptoms—but it had no long-acting injectable option that could be conveniently administered in an outpatient clinic without an extended monitoring period. The monthly subcutaneous format with no loading dose, no oral supplementation, and no post-injection observation requirement is a combination that should meaningfully lower the bar for transitioning appropriate patients to LAI therapy.
Teva expects U.S. commercial availability in the coming weeks. The European Medicines Agency has accepted a marketing authorization application for Weltruza, with a European decision expected in 2027.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients with schizophrenia or other psychiatric conditions should consult a qualified mental health professional before making any changes to their treatment.
[…] market context is active. We recently reported on the FDA approval of Teva’s monthly olanzapine injection Weltruza, an example of how formulation, not just new molecules, is changing schizophrenia care, and on the […]